Business Strategy Overview
Our acquisition and value creation strategy is to identify, acquire and, after our initial business combination, further accelerate the growth of a company in the pharmaceutical industry. We believe our management team’s knowledge, and our decades of experience and relationships across this industry can effect a positive transformation or augmentation of an existing business model through implementing proven business strategies within the pharmaceutical industry.
Team Expertise and Market Approach
Our team is well-positioned to originate attractive investment opportunities and has a history of executing various business transactions in multiple geographies and under varying economic and financial market conditions.
Our team will identify potential acquisition targets by leveraging existing relationships in combination with the market research data that aligns with the company’s strategic goals and priorities.
Our team will identify potential acquisition targets by leveraging existing relationships in combination with the market research data that aligns with the company’s strategic goals and priorities.
Criteria for
Acquisition Targets
Market size, growth potential, competition, and barriers to entry are all essential factors to consider as we identify the acquisition target. Our team intends to utilize an in-depth evaluation process of potential acquisition targets based on financial performance, strategic fit, and potential synergies as well as the company’s products and services to ensure our target is aligned.
Navigating Regulatory Challenges
Although the pharmaceutical industry is highly regulated, and there are many legal and regulatory considerations that companies must consider, such as licensing requirements, export controls, and liability issues. Our sponsor’s expertise and track record in the pharmaceutical space will help mitigate these factors by proactively advising potential target companies on navigating these issues.
Reducing Supply Chain Risks
We believe that it is possible to mitigate risks in the U.S. medical supply chain by investing in companies that will reduce America’s overreliance on the production of pharmaceuticals from concentrated geographic regions through investments in strategic on-shoring of advanced domestic manufacturing technologies for critical drugs.
Strategic Goals for Business Combination
To achieve these goals, we will aim to complete our initial business combination with one or more target companies that can deliver a solution to (1) the lack of supply chain visibility into where and by whom critical drug products are manufactured, and (2) the inability to accurately predict and proactively relieve ongoing and future drug shortages.
Future of the Pharmaceutical Business
We believe that we have an important role in the future of the pharmaceutical business. With a successful series of target acquisitions, the result will be a fully integrated competitive cost business with vast expertise. The aim will be for this business to have end-to-end capability—from plant-based raw material production for a spectrum of controlled substances (the Active Pharmaceutical Ingredients, or APIs) to drug manufacturing and prescriptions filled by pharmacies or directly to the patients.
Addressable Market and Revenue Growth
The post-business combination company would aim to grow revenues building on an addressable market for the $44 billion plant-based production segment, API market, and generic medications. As a full-spectrum producer, the finished product would allow the post-business combination company to disrupt the current situation in the pharmaceutical market at a competitive cost while all operations from the beginning of a product lifecycle to its end-user application are made in America.
Mitigating National Health and Security Risks
The complete solution will aim to provide supply chain resilience while mitigating identified national health and security risks. We believe that the deliverable of the post-business combination company over a lifecycle from seed to the finished generic drug, delivered to the pharmacy or patient directly, could mitigate an identified national security risk.
Leveraging Advanced Technologies
The business model will seek to guarantee production serviced by clean advanced technology leveraging artificial intelligence in controlled environments that are premised on advanced production technology in an energy-efficient manner while developing new continuous manufacturing processes for critical drugs and active pharmaceutical ingredients.
Addressing Drug Shortages
Shortages of critical medications continue to rise—including drugs used in hospital emergency rooms and to treat cancer, prescription medications, and even common over-the-counter treatments like children’s cold and flu medicine. Drug shortages are not a new problem. They are caused by a number of factors, including economic drivers, insufficient supply chain visibility, and a continued U.S. overreliance on both foreign and geographically concentrated sources for medications and their raw materials.
Impact on Patient Care and Costs
These shortages have cascading effects on patient care, causing delays in treatment, increasing the risk of medication errors, and requiring the use of less effective alternative treatments. Hospitals have also experienced increased costs, medication waste, and limited staffing capacity to address and remedy shortages.
Commitment to American-Made Pharmaceuticals
We believe that the post-business combination company will be able to become a new competitive cost producer of drugs made in America. Onboarding the production back to the U.S. creates jobs, mitigates national security risks, and will ensure the American people will have clean, pure, cost-efficient medications through a resilient supply chain made in America.